Ucb Biopharma Srl

This study tests if adding dapirolizumab pegol to standard lupus treatments can better control moderate to severe disease. About 450 adults with active lupus will receive the drug or a placebo for 48 weeks. The goal is to reduce lupus symptoms and flares without worsening overall…

This study compares two ways of giving bimekizumab—an IV infusion versus a standard shot—to see if the IV works just as well. About 392 adults with active psoriatic arthritis or axial spondyloarthritis will take part. The main goal is to check drug levels in the blood and watch f…

This study tests a drug called bimekizumab in children and teenagers aged 9 to 17 with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The main goal is to see how the drug moves through the body and if it is safe. About 40 participants wil…

This study tests an investigational drug called zilucoplan in 8 children (ages 2-17) with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, its safety, and whether it helps control symptoms. Participant…

This study tests a drug called bimekizumab in children aged 2 to 17 with active juvenile arthritis (enthesitis-related arthritis or juvenile psoriatic arthritis). The goal is to measure how the drug moves through the body and check for side effects. About 40 children will take pa…

This early-stage study is testing a new drug, UCB5285, in healthy volunteers to see if it is safe and how the body processes it. About 96 healthy adults, including some of Japanese descent, will receive a single dose. This study does not aim to treat any disease, but to gather im…

This study looks at how much of the drug bimekizumab passes into the breast milk of mothers who are already taking it for conditions like psoriasis or arthritis. About 20 breastfeeding women will provide milk samples over several weeks. The goal is to understand possible exposure…

This study looks at how much of the drug zilucoplan and its breakdown products end up in the breast milk of healthy women who are breastfeeding. About 15 women who are at least 6 weeks postpartum and plan to stop breastfeeding will take daily injections of zilucoplan. Researchers…